🌍 Market Size & Growth Projections

According to Acumen Research and Consulting, the global Allergy Care Market diagnostics and therapeutics market expanded from US $31.4 billion in 2022 to US $57.9 billion by 2032, at a 6.4 % CAGR between 2023 and 2032 . Grand View Research reports similar growth: from US $33.06 billion in 2023, increasing at an 8.7 % CAGR to reach nearly US $58.3 billion by 2030 . More optimistic forecasts by ResearchAndMarkets project the market surpassing US $104.5 billion by 2034, with an impressive 11 % CAGR from 2024–2034 .

These projections reflect robust demand driven by rising allergy prevalence, coupled with investment in cutting-edge diagnostics and novel therapies.

🧩 Key Market Segments

1. Diagnostics

Advancements in allergy diagnostics—spanning in vivo (skin prick tests) and in vitro (blood-based assays)—are central to precise and personalized treatment. AI, molecular diagnostics, and home-based testing are leveling up allergy identification :

• Thermo Fisher launched the VIDAS Allergy Screen Plus in December 2023; Siemens Healthineers partnered with Minaris Medical in late 2023 on point-of-care diagnostics .

• Thermo Fisher’s Phadia ImmunoCAP continues to dominate, while HYCOR’s NOVEOS immunoanalyzer enables efficient low-volume testing .

• Component-resolved diagnostics (CRD) and multiplex assays are growing, aiding molecular profiling and precision allergen mapping .

2. Therapeutics

This segment comprises pharmacotherapy (antihistamines, corticosteroids), immunotherapies (SCIT/SLIT), biologics, and treatment for food allergies. Growth trends highlight:

• Immunotherapies (especially SLIT) and biologics are accelerating, while traditional drugs maintain steady demand.

• Recent U.S. FDA expansion is seen with SLIT pills like ODACTRA for dust mite allergy .

• Allergy Partners expanded availability of PALFORZIA (an FDA-approved peanut oral immunotherapy) through Aimmune collaboration .

👥 Leading Companies & Strategic Moves

Key players are driving innovation via diagnostics platforms, immunotherapies, partnerships, and M&A:

• Thermo Fisher Scientific (Phadia ImmunoCAP) remains a diagnostic pioneer; launched rapid IgE component panels and acquired Phadia .

• Siemens Healthineers released an AI-powered allergy diagnostic platform integrated into broader systems in mid-2024 .

• bioMérieux, R‑Biopharm, Omega Diagnostics, HYCOR, and DASIT are strengthening portfolios through alliances and new platforms.

• ALK‑Abelló, a global immunotherapy specialist, leads in SLIT/SCIT, generating ~DKK 4.8 billion (~US $700 million) in revenue in 2023 .

• Notable M&A includes Danaher’s acquisition of Immucor in late 2023 and Nestlé’s transfer of the peanut OIT Palforzia to Stallergenes Greer .

🚀 Innovation Trends & Technological Integration

1. AI-driven diagnostics: Automated wheal detection in skin prick testing (e.g., SPAT device) improves accuracy and consistency .

2. Component-resolved diagnostics & multiplex assays: Allow for fine-grained allergen profiling .

3. Point-of-care and home testing: Growth in on-site panels (Thermo Fisher, Siemens) and home allergy test kits tied to telemedicine .

4. Molecular diagnostics and biomarkers: While primarily focused on oncology, platforms from Biodesix indicate a trend toward proteomic/genomic biomarker use—potentially applicable to complex allergic conditions .

📊 Regional Landscape

• North America holds ~36–39 % of the market, fueled by high awareness and reimbursement systems .

• Europe is strong in SLIT adoption, with regulatory backing and active academic adoption of CRD .

• Asia-Pacific leads in regional growth, supported by rapid infrastructure expansion in China, Japan, and India.

• Emerging markets (Latin America, MEA) have untapped potential, particularly in diagnostics access and immunotherapy uptake.

🎯 Strategic Opportunities

• Integrated care models: Linking AI-enabled diagnostics with personalized immunotherapy or biologics can improve outcomes.

• Home-based diagnostics & telehealth: Investing in at-home testing alongside telemedicine platforms can increase accessibility and adherence.

• Pediatric and non-invasive growth: Focus on child-friendly testing (e.g., SPAT, multiplex panels) aligns with demographic trends.

• Emerging market ventures: Expanding capacity in Asia-Pacific and LATAM with localized panels and strategic partnerships.

• M&A and collaborations: Combining diagnostic and therapeutic firms can streamline allergen care ecosystems and product pipelines.

⚠️ Challenges & Considerations

• High development and regulatory costs: Particularly for biologics, CRD technologies, and AI-centric diagnostics.

• Reimbursement variability: Inadequate coverage in emerging economies may slow adoption.

• Healthcare infrastructure gaps: Rural regions lag in specialist access, hampering broad deployment.

• Economic pressures: Rising costs of living could restrain spend on premium diagnostics and therapies.

🔮 Outlook to 2032

By 2032, the allergy diagnostics and therapeutics market is projected to nearly double in value, approaching US $60–80 billion, with extended forecasts predicting over US $100 billion by 2034 . Growth will be anchored by:

• Diagnostics: AI integration, CRD, multiplex, and point-of-care testing.

• Therapeutics: Expanded SLIT, OIT, and biologic offerings, supported by regulatory approvals and biosimilar introductions.

• Global expansion: Strong growth in Asia-Pacific, with untapped opportunity in emerging regions.

✅ In Summary

• Diagnostics: Technological innovation and integration remain key differentiators.

• Therapeutics: Immunotherapies and biologics are the primary growth drivers.

• Players: Thermo Fisher, Siemens, ALK-Abelló, bioMérieux, HYCOR, Danaher, Stallergenes Greer.

• Trends: Precision diagnostics, AI-enabled platforms, home/POC testing, pediatric focus, emerging markets push.

• Outlook: Sustained growth through innovation, partnerships, and regional expansion.

The projected shift toward personalized, technology-enabled allergy care is reinforcing the industry's transition from reactive to proactive and precision-driven regimes—ushering in a more integrated and effective ecosystem by 2032.